[go: up one dir, main page]

WO2001047509A3 - Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions - Google Patents

Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions Download PDF

Info

Publication number
WO2001047509A3
WO2001047509A3 PCT/GB2000/005006 GB0005006W WO0147509A3 WO 2001047509 A3 WO2001047509 A3 WO 2001047509A3 GB 0005006 W GB0005006 W GB 0005006W WO 0147509 A3 WO0147509 A3 WO 0147509A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
diabetes mellitus
cardiac conditions
agent used
insuline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/005006
Other languages
French (fr)
Other versions
WO2001047509A2 (en
Inventor
Robin Edward Buckingham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930688.8A external-priority patent/GB9930688D0/en
Priority claimed from GBGB9930690.4A external-priority patent/GB9930690D0/en
Priority claimed from GBGB9930689.6A external-priority patent/GB9930689D0/en
Priority claimed from GBGB9930692.0A external-priority patent/GB9930692D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to JP2001548104A priority Critical patent/JP2003518493A/en
Priority to EP00987579A priority patent/EP1261373A2/en
Priority to AU23826/01A priority patent/AU2382601A/en
Publication of WO2001047509A2 publication Critical patent/WO2001047509A2/en
Anticipated expiration legal-status Critical
Publication of WO2001047509A3 publication Critical patent/WO2001047509A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for the treatment of diabetes mellitus, especially Type II diabetes and the cardiac conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, such as Compound (I), and an agent used in the treatment of the cardiac conditions associated with diabetes mellitus.
PCT/GB2000/005006 1999-12-24 2000-12-22 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions Ceased WO2001047509A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001548104A JP2003518493A (en) 1999-12-24 2000-12-22 New treatment methods
EP00987579A EP1261373A2 (en) 1999-12-24 2000-12-22 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
AU23826/01A AU2382601A (en) 1999-12-24 2000-12-22 Novel method of treatment

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9930688.8A GB9930688D0 (en) 1999-12-24 1999-12-24 Novel method of treatment
GB9930689.6 1999-12-24
GBGB9930690.4A GB9930690D0 (en) 1999-12-24 1999-12-24 Novel method of treatment
GB9930688.8 1999-12-24
GBGB9930689.6A GB9930689D0 (en) 1999-12-24 1999-12-24 Novel method of treatment
GBGB9930692.0A GB9930692D0 (en) 1999-12-24 1999-12-24 Novel method of treatment
GB9930690.4 1999-12-24
GB9930692.0 1999-12-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/168,872 A-371-Of-International US20030060489A1 (en) 1999-12-24 2000-12-22 Novel method of treatment
US10/803,300 Continuation US20040176373A1 (en) 1999-12-24 2004-03-18 Novel method of treatment

Publications (2)

Publication Number Publication Date
WO2001047509A2 WO2001047509A2 (en) 2001-07-05
WO2001047509A3 true WO2001047509A3 (en) 2002-09-12

Family

ID=27451929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/005006 Ceased WO2001047509A2 (en) 1999-12-24 2000-12-22 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions

Country Status (4)

Country Link
EP (1) EP1261373A2 (en)
JP (1) JP2003518493A (en)
AU (1) AU2382601A (en)
WO (1) WO2001047509A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354602B1 (en) * 2000-12-26 2006-10-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
CN1465712A (en) * 2002-07-05 2004-01-07 安徽省生物医学研究所 Kit, method, software and compound medicine for predicting effect of ACEI antihypertensive medicine
EP2106260B8 (en) 2007-01-25 2018-04-04 Naia Metabolic, Inc. Insulin sensitisers and methods of treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861666A2 (en) * 1995-06-20 1998-09-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in treatment of diabetes
EP0930076A1 (en) * 1996-07-15 1999-07-21 Sankyo Company Limited Medicinal compositions
WO2000027434A1 (en) * 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Combinations comprising a beta-agonist and a further antidiabetic agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861666A2 (en) * 1995-06-20 1998-09-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in treatment of diabetes
US5965584A (en) * 1995-06-20 1999-10-12 Takeda Chemical Industries, Ltd. Pharmaceutical composition
EP0930076A1 (en) * 1996-07-15 1999-07-21 Sankyo Company Limited Medicinal compositions
WO2000027434A1 (en) * 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Combinations comprising a beta-agonist and a further antidiabetic agent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAGOGO-JACK S ET AL: "PATHOPHYSIOLOGY OF TYPE 2 DIABETES AND MODES OF ACTION OF THERAPEUTIC INTERVENTIONS", ARCHIVES OF INTERNAL MEDICINE, XX, XX, vol. 157, no. 16, 8 September 1997 (1997-09-08), pages 1802 - 1817, XP000872498 *
HOSOKAWA, M. ET AL: "Troglitazone inhibits bicarbonate secretion in rat and human duodenum", J. PHARMACOL. EXP. THER. (1999), 290(3), 1080-1084, XP008002057 *
SHIMOYAMA, MASAKI ET AL: "Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.", DIABETES, (MARCH, 1999) VOL. 48, NO. 3, PP. 609-615., XP001035237 *

Also Published As

Publication number Publication date
JP2003518493A (en) 2003-06-10
EP1261373A2 (en) 2002-12-04
AU2382601A (en) 2001-07-09
WO2001047509A2 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
EP1787646A3 (en) Novel method of treatment
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
MXPA02012763A (en) Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus.
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
CA2329004A1 (en) Combination of insulin sensitizer with anorectic for treating or preventing diabetes
YU37301A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
IL198783A0 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
AU2924084A (en) Oral antidiabetic composition
CA2208047A1 (en) Increasing creatine and glycogen concentration in muscle
WO1996015784A3 (en) 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same, and use thereof for treating insulin resistance
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
AP2000001735A0 (en) Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.
MY125855A (en) Treatment of diabetes with a thiazolidinedione and sulphonylurea
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
HK1041201A1 (en) Compatibility of beta agonists and antidiabetic agents
WO2001070236A8 (en) Preventing and/or treating diabetes mellitus
AU2003288793A1 (en) Pharmaceutical compound containing silymarin and carbopol®, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method
NZ503862A (en) Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia
ECSP982542A (en) NEW METHOD OF TREATMENT III
ECSP982593A (en) NEW METHOD OF TREATMENT VI
TR200000957T2 (en) The use of thiazolidinedione in the treatment of hyperglycemia
HUP0002668A2 (en) Treatment of diabetes with thiazolidinedione and metformin
ECSP982591A (en) NEW METHOD OF TREATMENT IV

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 548104

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000987579

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10168872

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000987579

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000987579

Country of ref document: EP